.TRS_Editor P{font-family:宋体;font-size:16pt;}.TRS_Editor DIV{font-family:宋体;font-size:16pt;}.TRS_Editor TD{font-family:宋体;font-size:16pt;}.TRS_Editor TH{font-family:宋体;font-size:16pt;}.TRS_Editor SPAN{font-family:宋体;font-size:16pt;}.TRS_Editor FONT{font-family:宋体;font-size:16pt;}.TRS_Editor UL{font-family:宋体;font-size:16pt;}.TRS_Editor LI{font-family:宋体;font-size:16pt;}.TRS_Editor A{font-family:宋体;font-size:16pt;} .TRS_Editor P{font-family:宋体;font-size:16pt;}.TRS_Editor DIV{font-family:宋体;font-size:16pt;}.TRS_Editor TD{font-family:宋体;font-size:16pt;}.TRS_Editor TH{font-family:宋体;font-size:16pt;}.TRS_Editor SPAN{font-family:宋体;font-size:16pt;}.TRS_Editor FONT{font-family:宋体;font-size:16pt;}.TRS_Editor UL{font-family:宋体;font-size:16pt;}.TRS_Editor LI{font-family:宋体;font-size:16pt;}.TRS_Editor A{font-family:宋体;font-size:16pt;}   在经历年内一轮强势上涨后，医药板块的上行势头近期有所放缓，“翻倍基”数量也明显收缩。   数据显示，三季度医药主题基金一度出现翻倍数量的阶段性高点，但截至11月28日仅剩两只产品维持年内翻倍收益。近三个月，头部医药ETF规模出现了下滑，资金情绪由此前的集中加仓转向更偏谨慎的观望。   业内人士认为，当前
=*=*=*=*=*=
当前为第1/3页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页